2025 cagrilintide semaglutide cagrisema phase 3 results 2025 Novo Nordisk has officially filed for FDA approval of CagriSema, a powerful new once-weekly injection that combines a GLP-1 receptor agonist with an amylin analogue, setting the stage for the next major Novo Nordisk's CagriSema outperforms Ozempic

Description

Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammation

Historically, there was significant concern for notoriety bias (i.e., increased likelihood of case reporting when patients are exposed to a drug with a negative reputation), which was mitigated by studying disproportionality signals

For example, Valonen and colleagues developed a 3D-woven poly(-caprolactone) (PCL) scaffold with an aggregate modulus of 550 kPa, well within the range of native articular cartilage